In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prolifix Ltd.

Division of Onxeo SA
www.prolifix.co.uk

Latest From Prolifix Ltd.

M&A Makes Sense for Procognia

Procognia's acquisition of fellow Apax portfolio company Sense Proteomic could indicate a more proactive stance from VCs intent on consolidating their bets behind likely winners.
BioPharmaceutical Europe

Medical Research Council Technology

Britain's Medical Research Council has done a lot over the last decade to develop its technology transfer activities. Almost half of the 16 spin-off companies based on MRC research have appeared in the last two years. One important catalyst for this increase in spin-out activity was the founding in 1998 of a venture capital fund with priority access to companies based on MRC-owned technology, the UK Medical Ventures Fund/MVM Ltd. More recently, the creation of Medical Research Council Technology, bringing together three geographically distinct units involved in technology transfer, has led to a simpler, more efficient structure and better staff retention.
BioPharmaceutical Strategy

Plugging One VC Gap

Two years ago, the UK's publicly-funded Medical Research Council set up a new venture fund with a right of first refusal to all MRC-funded technology. Its British VC competitors greeted the newcomer, which claimed to want to fill a gap in seed-stage investing, coolly--they felt that no such gap existed and that UK Medical Ventures Fund would have an unfair advantage. Whether they're still jealous is uncertain, but they are doing deals with the new fund, which has significantly stepped up the rate at which MRC technology is transferred to the marketplace.
Business Strategies Regulation

BioFocus PLC

Like many other small service-based companies operating today, BioFocus PLC synthesizes compounds, carries out molecular modelling experiments, analyzes quantitative structure-activity relationship (QSAR) and performs statistical data analysis. All of these services are fairly standard fare, these days. But BioFocus believes it has two unique technology sets that distinguish it from competitors. {PharmaScape} is a toolbox of scaffolds and monomers and their associated chemistries, and {Predictive Array Design} is a method for designing small, efficient compound libraries.
BioPharmaceutical Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Onxeo SA
  • Senior Management
  • Birgit Stattin-Norinder, CEO
    David Knowles, CFO
    Nicholas La Thangue, CSO
    Sarah Eccles, PhD, Head, Bus. Dev.
  • Contact Info
  • Prolifix Ltd.
    Phone: (44)
    B147 Second St.
    Harwell, Didcot, OX11 OTL
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register